Joseph T S Wee
Overview
Explore the profile of Joseph T S Wee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
2319
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neo J, Yip P, Ong E, Miao J, Chow W, Wee J, et al.
Oral Oncol
. 2023 Dec;
148:106655.
PMID: 38056062
Objectives: To characterize longitudinal changes in Epstein-Barr virus (EBV) DNA post-radiotherapy in nasopharyngeal carcinoma (NPC) patients, and investigate whether an early (0-2 weeks) or delayed (8-12 weeks) EBV DNA result...
2.
Poh S, Tan B, Yong F, Fong K, Wee J, Tan T, et al.
Holist Integr Oncol
. 2023 Jul;
2(1):17.
PMID: 37520028
Purpose Or Objective: The COVID-19 pandemic has resulted in significant healthcare implications, with care for cancer patients compromised due to resource diversion towards battling the pandemic. We aim to investigate...
3.
4.
The Hunt for the perfect biomarker in nasopharyngeal carcinoma-the "race" beyond Epstein-Barr virus?
Tan M, Wee J, Chua M
Transl Cancer Res
. 2022 Feb;
8(5):1659-1662.
PMID: 35116914
No abstract available.
5.
Huang L, Zhang X, Bai Y, Chua K, Xie Y, Shu X, et al.
Oral Oncol
. 2021 Feb;
115:105222.
PMID: 33610004
Background: There is no standard-of-care for recurrent, metastatic nasopharyngeal carcinoma (rmNPC) after first-line chemotherapy. Here, we report the efficacy and safety data of apatinib in rmNPC patients. Methods: Thirty-five biopsy-proven...
6.
Chen Y, Ismaila N, Chua M, Colevas A, Haddad R, Huang S, et al.
J Clin Oncol
. 2021 Jan;
39(7):840-859.
PMID: 33405943
Purpose: The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC)....
7.
Huang L, Sim A, Wu Y, Liang Z, Li K, Du Y, et al.
Ther Adv Med Oncol
. 2020 Nov;
12:1758835920970050.
PMID: 33240398
Background: Lactate dehydrogenase (LDH) is a known prognostic biomarker for the endemic variant of nasopharyngeal carcinoma (NPC). Here, we investigate whether serial changes in LDH level between chemotherapy (CT) cycles...
8.
Chua K, Fehlings M, Yeo E, Nardin A, Sumatoh H, Chu P, et al.
Int J Radiat Oncol Biol Phys
. 2020 Jun;
108(1):70-80.
PMID: 32544576
Purpose: Improved antitumor responses have been observed in patients after combination radiation therapy (RT) and immune checkpoint blockade (ICB). Whether these clinical responses are linked to the host systemic immune...
9.
Miao J, Di M, Chen B, Wang L, Cao Y, Xiao W, et al.
Int J Radiat Oncol Biol Phys
. 2020 Apr;
107(4):672-682.
PMID: 32272183
Purpose: Current guideline recommends a uniform method of delineation of subclinical disease within the primary clinical target volume (CTVp) for all stages of nasopharyngeal carcinoma (NPC). We performed a prospective...
10.